New AIDS drug shows 'phenomenal' results

Jan 02, 2007

AIDS researchers said a new drug shows promise for inhibiting the HIV virus in patients new to treatment or those currently taking a drug cocktail.

Clinical studies of the drug, called an integrase inhibitor, showed that, when combined with two existing drugs, it reduced the virus to undetectable levels in nearly 100 percent of HIV patients prescribed a drug regimen for the first time, The Los Angeles Times said Tuesday. It had a similar effect in 72 percent of salvage therapy patients, who take a mixture of existing medications aimed at stalling the virus until new drugs appear.

The drug essentially prevents the virus' DNA from integrating with a host's cells, inhibiting its ability to replicate itself.

The U.S. Food and Drug Administration should approve it in mid-2007. Manufacturer Merck & Co. is making it available sooner to patients in desperate straits.

"They tested it on some people who were in deep, deep salvage therapy, and even those people did remarkably well," Dr. Steven Deeks, a University of California, San Francisco salvage therapy authority, told the Times. "It seems to be a truly phenomenal drug that ... is changing the whole way we think about the management of these patients."

Copyright 2007 by United Press International

Explore further: HIV+ women respond well to HPV vaccine

add to favorites email to friend print save as pdf

Related Stories

Metabolic errors can spell doom for DNA

Jan 31, 2012

Many critical cell functions depend on a class of molecules called purines, which form half of the building blocks of DNA and RNA, and are a major component of the chemicals that store a cell’s energy. ...

A new approach to medicine

Sep 24, 2010

(PhysOrg.com) -- University of Connecticut researchers are exploring how to take a patient's own cells, re-engineer them, and replace them in the body.

Recommended for you

HIV+ women respond well to HPV vaccine

17 hours ago

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

HIV battle must focus on hard-hit streets, paper argues

Apr 10, 2014

In U.S. cities, it's not just what you do, but also your address that can determine whether you will get HIV and whether you will survive. A new paper in the American Journal of Public Health illustrates the ef ...

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

New clinical trial launched for advance lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

Sony's PlayStation 4 sales top seven million

Sony says it has sold seven million PlayStation 4 worldwide since its launch last year and admitted it can't make them fast enough, in a welcome change of fortune for the Japanese consumer electronics giant.